Concr is a mission-driven techbio company that uses established methods from astrophysics to accurately predict patient outcomes and treatment response to novel and existing cancer therapies. Our unique approach allows iterative learning between disparate and fragmented data across all stages of a drug’s journey into the clinic, removing the need for ‘big data’ and yielding most accurate multi-modal tumour models. Concr’s cloud native platform – FarrSight® – empowers researchers to computationally simulate clinical trials, make advanced predictions about therapeutic response and biomarkers, and perform standard bioinformatics analyses directly. Concr is headquartered in London, with a wholly-owned subsidiary in Brisbane, Australia. The company is a venture capital-backed enterprise, with investors including the University of Cambridge Enterprise, R42 Group, Oncology Ventures, Debiopharm, Cambridge Angels, Deep Science Ventures and SyndicateRoom.
Parallel Carbon is creating the hardware platform required for a post-fossil-fuel society. To eliminate emissions, they are developing technology that removes carbon dioxide from the atmosphere while producing hydrogen. Their mission is to provide the most scalable solution to climate change.
Aquature is creating a decentralized platform to assist enterprises in transitioning to sustainable wastewater treatment, saving money and gaining independence through the advancement of circularity concepts .Aquature designs, owns, installs and operates your wastewater treatment system with no upfront capital investment. They only pay a service charge per cubic metre of wastewater treated and for the green chemicals you want to recirculate and use in your process.